Cellosaurus logo
expasy logo

Cellosaurus RMG-I (CVCL_1662)

[Text version]
Cell line name RMG-I
Synonyms RMGI; RMG1; RMG-1
Accession CVCL_1662
Resource Identification Initiative To cite this cell line use: RMG-I (RRID:CVCL_1662)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: MD Anderson Cell Lines Project.
Population: Japanese.
Doubling time: 60 hours (PubMed=3154025); 40 hours (PubMed=25984343); ~3 days (Note=Lot 07022008), ~72 hours (Note=Lot 12252012), ~57 hours (Note=Lot 01212019) (JCRB=IFO50315); ~30 hours (Note=Lot 07052011), ~31 hours (Note=Lot 07142017), ~33 hours (Note=Lot 02042020) (JCRB=JCRB0172).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: CRISPR phenotypic screen.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Genome sequenced.
Omics: Protein expression by reverse-phase protein arrays.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
Sequence variations
  • Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=8980248).
  • Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg58Arg (c.174A>C) (p.Ser73Arg, c.217A>C); ClinVar=VCV000128200; Zygosity=Unspecified (PubMed=25846456).
  • Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
  • Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (Cosmic-CLP=909699; DepMap=ACH-000719).
HLA typing Source: PubMed=25960936
Class I
HLA-AA*24:02,24:02
HLA-BB*40:02,40:02
HLA-CC*03:04,03:04

Source: PubMed=26589293
Class I
HLA-AA*24:02,24:02
HLA-BB*40:02,40:02
HLA-CC*03:04,03:04
Class II
HLA-DRDRB1*11:02,11:02
Genome ancestry Source: PubMed=30894373

Origin% genome
African0
Native American0.61
East Asian, North81.67
East Asian, South17.3
South Asian0
European, North0.42
European, South0
Disease Ovarian clear cell adenocarcinoma (NCIt: C40078)
Clear cell adenocarcinoma of the ovary (ORDO: Orphanet_398971)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_IS64 (RMG-I-C)CVCL_IS65 (RMG-I-H)
Sex of cell Female
Age at sampling 34Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP=909699; JCRB=IFO50315; JCRB=JCRB0172; PubMed=25877200; PubMed=30485824

Markers:
AmelogeninX
CSF1PO10
D3S135815,16
D5S81812
D7S82011
D8S117915,16
D13S3178,12
D16S5399,10
D18S5113,15
D21S1129,30
FGA25,26
Penta D9,10
Penta E15,16
TH016,7
TPOX11
vWA17,18

Run an STR similarity search on this cell line
Web pages https://tcpaportal.org/mclp/
Publications

PubMed=3154025
Nozawa S., Tsukazaki K., Sakayori M., Jeng C.-H., Iizuka R.
Establishment of a human ovarian clear cell carcinoma cell line (RMG-I) and its single cell cloning -- with special reference to the stem cell of the tumor.
Hum. Cell 1:426-435(1988)

PubMed=8980248; DOI=10.1002/(SICI)1097-0215(19961220)69:6<466::AID-IJC8>3.0.CO;2-2
Ichikawa Y., Yoshida S., Koyama Y., Hirai M., Ishikawa T., Nishida M., Tsunoda H., Kubo T., Miwa M., Uchida K.
Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors.
Int. J. Cancer 69:466-470(1996)

CLPUB00481
Kuno H., Yoshida T.
Detection of human papillomavirus types 16, 18, and 33 in cell lines derived from human genital organs by polymerase chain reaction.
Res. Commun. Inst. Ferment. 18:6-12(1997)

PubMed=11330945; DOI=10.1006/gyno.2001.6132
Watanabe T., Imoto I., Kosugi Y., Ishiwata I., Inoue S., Takayama M., Sato A., Inazawa J.
A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization.
Gynecol. Oncol. 81:172-177(2001)

PubMed=12417041; DOI=10.1111/j.1349-7006.2002.tb01213.x; PMCID=PMC5926887
Watanabe T., Imoto I., Katahira T., Hirasawa A., Ishiwata I., Emi M., Takayama M., Sato A., Inazawa J.
Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers.
Jpn. J. Cancer Res. 93:1114-1122(2002)

PubMed=17671176; DOI=10.1158/0008-5472.CAN-06-4567
Kikuchi R., Tsuda H., Kanai Y., Kasamatsu T., Sengoku K., Hirohashi S., Inazawa J., Imoto I.
Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.
Cancer Res. 67:7095-7105(2007)

PubMed=20081105; DOI=10.1210/me.2009-0295; PMCID=PMC2817607
Nagaraja A.K., Creighton C.J., Yu Z.-F., Zhu H.-F., Gunaratne P.H., Reid J.G., Olokpa E., Itamochi H., Ueno N.T., Hawkins S.M., Anderson M.L., Matzuk M.M.
A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.
Mol. Endocrinol. 24:447-463(2010)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22705003; DOI=10.1016/j.humpath.2012.03.011
Rahman M., Nakayama K., Rahman M.T., Nakayama N., Ishikawa M., Katagiri A., Iida K., Nakayama S., Otsuki Y., Shih I.-M., Miyazaki K.
Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Hum. Pathol. 43:2197-2206(2012)

PubMed=23430509; DOI=10.1007/s13577-013-0062-y
Itamochi H., Kato M., Nishimura M., Oumi N., Oishi T., Shimada M., Sato S., Naniwa J., Sato S., Nonaka M., Kudoh A., Terakawa N., Kigawa J., Harada T.
Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.
Hum. Cell 26:121-127(2013)

PubMed=23839242; DOI=10.1038/ncomms3126; PMCID=PMC3715866
Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.
Evaluating cell lines as tumour models by comparison of genomic profiles.
Nat. Commun. 4:2126.1-2126.10(2013)

PubMed=24023729; DOI=10.1371/journal.pone.0072162; PMCID=PMC3762837
Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M., Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R., Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.
Type-specific cell line models for type-specific ovarian cancer research.
PLoS ONE 8:E72162-E72162(2013)

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35; PMCID=PMC4432652
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25846456; DOI=10.3892/ijo.2015.2951
Takenaka M., Saito M., Iwakawa R., Yanaihara N., Saito M., Kato M., Ichikawa H., Shibata T., Yokota J., Okamoto A., Kohno T.
Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.
Int. J. Oncol. 46:2389-2398(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028
Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J., Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A., Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J., Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.
Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.
Cell Rep. 18:2343-2358(2017)

PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096; PMCID=PMC6481945
Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M., Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R., Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J., Velculescu V.E., Scharpf R.B.
Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.
Cell Rep. 25:2617-2633(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) JCRB; IFO50315
JCRB; JCRB0172
JCRB; FDSC0027 - Discontinued
Cell line databases/resources CLO; CLO_0037103
cancercelllines; CVCL_1662
Cell_Model_Passport; SIDM00352
CGH-DB; 336-2
CGH-DB; 9362-4
Cosmic-CLP; 909699
DepMap; ACH-000719
LINCS_LDP; LCL-1805
Anatomy/cell type resources BTO; BTO:0004930
Biological sample resources BioSample; SAMN03471003
BioSample; SAMN10988355
CRISP screens repositories BioGRID_ORCS_Cell_line; 1000
Chemistry resources ChEMBL-Cells; CHEMBL3308778
ChEMBL-Targets; CHEMBL1075564
GDSC; 909699
PharmacoDB; RMGI_1320_2019
PubChem_Cell_line; CVCL_1662
Encyclopedic resources Wikidata; Q54950664
Experimental variables resources EFO; EFO_0006746
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM416682
GEO; GSM659403
GEO; GSM827210
GEO; GSM887544
GEO; GSM888627
GEO; GSM1001429
GEO; GSM1001430
GEO; GSM1176283
GEO; GSM1340592
GEO; GSM1670383
GEO; GSM2475004
Polymorphism and mutation databases Cosmic; 909699
Cosmic; 931360
Cosmic; 945377
Cosmic; 1152556
Cosmic; 1223319
Cosmic; 1328068
Cosmic; 1708378
Cosmic; 1889262
Cosmic; 2482708
Cosmic; 2582799
IARC_TP53; 21289
LiGeA; CCLE_443
Progenetix; CVCL_1662
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update02-May-2024
Version number39